- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06315322
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: UCB Cares
- Phone Number: 1-844-599-2273 (USA)
- Email: UCBCares@ucb.com
Study Contact Backup
- Name: UCB Cares
- Phone Number: 001 844 599 2273
- Email: UCBCares@ucb.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who previously participated in EP0132 (NCT05109234) and/or N01269 (NCT04666610) and qualify for entry into EP0224 as per the EP0132 or N01269 protocol with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE)
- Participants for whom a reasonable benefit from long-term administration of Brivaracetam (BRV) is expected in the opinion of the Investigator
- Male and female A male participant must agree to use contraception during the treatment period and for at least 2 days after the final dose of investigational medicinal product (IMP) and refrain from donating sperm during this period.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
◦ Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the final dose of IMP.
- Capable of and provides informed consent/assent, and the participant's parent/legal representative/caregiver provides signed informed consent for minor participants, which includes compliance with the requirements and restrictions listed in the Informed Consent form (ICF)/Assent form and in this protocol
Exclusion Criteria:
- Participant has a history or presence of paroxysmal nonepileptic seizures
- Participant has severe medical, neurological, or psychiatric disorders or laboratory values which could, at the discretion of the Investigator, affect safe participation in the study or would preclude appropriate study participation
- Participant has hepatic impairment (Child Pugh Score A, B, or C) based on the Investigator's assessment
- Participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) (for participants 6 years of age or older) or clinical judgment (for participants younger than 6 years of age). The participant should be referred immediately to a Mental Healthcare Professional
- Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
- Participant has known fructose intolerance or a known hypersensitivity to any components of BRV or excipients or a drug with similar chemical structure
- Concomitant use of carbamazepine, felbamate, gabapentin, oxcarbazepine, phenobarbital, phenytoin, tiagabine, or vigabatrin
- Participant is receiving any investigational drugs or using any experimental devices in addition to BRV
- Participant meets a mandatory withdrawal criterion for N01269 or EP0132 or is experiencing an ongoing Serious adverse event (SAE)
- Participant has poor compliance with the visit schedule or IMP intake in the preceding study in the opinion of the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brivaracetam arm
Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
|
Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet [10, 25 or 50 mg] will be administered twice per day in equal doses.
Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution [10 mg/mL]) will be administered twice per day in equal doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (TEAEs) during the study
Time Frame: From Entry Visit up to the Safety Visit (up to 3 years)
|
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
|
From Entry Visit up to the Safety Visit (up to 3 years)
|
Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study
Time Frame: From Entry Visit up to the Safety Visit (up to 3 years)
|
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
|
From Entry Visit up to the Safety Visit (up to 3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of serious adverse events (SAEs) during the study
Time Frame: From Entry Visit up to the Safety Visit (up to 3 years)
|
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
|
From Entry Visit up to the Safety Visit (up to 3 years)
|
Incidence of IMP related TEAEs during the study
Time Frame: From Entry Visit up to the Safety Visit (up to 3 years)
|
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medicinal product (IMP).
|
From Entry Visit up to the Safety Visit (up to 3 years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EP0224
- 2023-508095-11-00 (Registry Identifier: EU Trial Number)
- U1111-1303-1174 (Other Identifier: Universal Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Absence Epilepsy
-
Assistance Publique - Hôpitaux de ParisCompletedChildhood Absence Epilepsy [Pyknolepsy]France
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedChildhood or Juvenile Absence EpilepsyFrance
-
UCB Biopharma SRLRecruitingChildhood Absence Epilepsy | Juvenile Absence EpilepsyUnited States, Australia, Georgia, Italy, Poland, Romania, Slovakia, Spain, Ukraine, Belgium
-
UCB Biopharma SRLEnrolling by invitationChildhood Absence Epilepsy | Juvenile Absence EpilepsyUnited States, Georgia, Italy, Romania, Ukraine, Slovakia, Spain
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedChildhood Absence EpilepsyUnited States
-
Eysz, Inc.University of Colorado, Denver; Wake Forest University Health Sciences; Children...RecruitingChildhood Absence Epilepsy | Absence Seizures | Epilepsy ComorbiditiesUnited States
-
Radius Pharmaceuticals, Inc.TerminatedChildhood Absence EpilepsyUnited States
-
Yale UniversityNational Institutes of Health (NIH)CompletedChildhood Absence EpilepsyUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.CompletedEpilepsy, Absence
Clinical Trials on Brivaracetam Film-coated tablet
-
UCB Biopharma SRLEnrolling by invitationChildhood Absence Epilepsy | Juvenile Absence EpilepsyUnited States, Georgia, Italy, Romania, Ukraine, Slovakia, Spain
-
Galapagos NVTerminatedSystemic Lupus ErythematosusSpain, Bulgaria, Moldova, Republic of, Poland, Ukraine
-
LG ChemCompleted
-
AstraZenecaQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
Novartis PharmaceuticalsCompletedChronic Iron Overload Due to Transfusion-dependant AnemiasItaly, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
-
UCB Pharma SACompleted
-
AstraZenecaParexelCompletedCoronary Artery Disease (CAD)United Kingdom
-
Chong Kun Dang PharmaceuticalCompletedGastrointestinal Stromal Tumors | Chronic Myeloid LeukemiaKorea, Republic of
-
Damanhour UniversityCompleted
-
H. Lundbeck A/SCompletedBioequivalence Study in Healthy SubjectsRussian Federation